Biotech

Biotech sits at the intersection of biology, computing, and capital, and that mix has never been more volatile or more consequential. The field encompasses drug discovery, gene and cell therapies, diagnostics, and the industrial tools that turn molecular insight into treatments. What makes this space compelling right now is the collision of two forces: artificial intelligence reshaping how candidates are identified and tested, and a funding environment that rewards some bets lavishly while starving others.

Generative biology and AI-driven discovery platforms are compressing timelines that once took years into months, drawing enormous investment from venture capital and pharmaceutical partners eager to de-risk the notoriously expensive drug pipeline. At the same time, the industry faces a persistent paradox—scientific breakthroughs that produce genuinely effective therapies don't always translate into viable businesses, leading to layoffs, restructurings, and shuttered programs even as the science advances.

Readers here will find coverage of the deals and funding rounds fueling AI-native biotech startups, the technical progress being made in computational drug design, and the harder business realities of clinical trials, regulatory hurdles, and commercialization. We track how established firms are adapting their R&D strategies, how smaller companies are trying to carve out defensible niches, and where the money is flowing—and where it's pulling back. Whether the news is a breakthrough platform, a funding milestone, or another round of job cuts, this hub is where the science and the business of biotech meet, offering the context needed to understand an industry defined by high risk, high reward, and increasingly, high-speed computation.